newsEnsovibep shows promise as an antiviral for COVID-1910 January 2022 | By Hannah Balfour (European Pharmaceutical Review)Phase II trial data suggests ensovibep (MP0420) significantly reduces SARS-CoV-2 viral load and reduces hospitalisation and death due to COVID-19.